MedTrace Logo

Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)

NCT02832128 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-05-24

No results posted yet for this study

Summary

The objective of this pilot study is to explore whether repeat doses of AUT00063 can provide an indication of improvement in performance of tests across a battery of speech and hearing assessments in cochlear implant users.

Conditions

Interventions

DRUG

AUT00063

4 capsules of 200 mg AUT00063, to take orally with food for 4 weeks

DRUG

Placebo

4 capsules of placebo, to take orally with food for 4 weeks

Sponsors & Collaborators

  • Autifony Therapeutics Limited

    lead INDUSTRY

Principal Investigators

  • Shakeel R Saeed, MD, FRCS (ORL) · Royal National Throat, Nose and Ear Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02832128 on ClinicalTrials.gov